PSY Shortwave Life Sciences Plc

TIDMPSY

RNS Number : 2576X

Psych Capital PLC

25 April 2023

25 April 2023

PSYCH CAPITAL PLC

("Psych Capital", or "the Company")

PSYCH Symposium returns to the European capital for psychedelic healthcare

PSYCH SYMPOSIUM 6th JULY, LONDON

After a sold-out conference in 2022, PSYCH Symposium is returning to bring together leading investors, regulators, scientists and industry leaders who are looking to transform the future of healthcare through psychedelic medicine.

The event has become one of the most highly anticipated conferences in the field of psychedelic healthcare, attracting industry leaders and professionals from around the world. The symposium provides a platform for experts to discuss the latest research, development and commercialisation of psychedelics for various medical conditions.

PSYCH Symposium aims to promote the integration of psychedelics into mainstream medicine, and attendees will have the opportunity to connect with leading researchers in the field, network with peers and learn about the latest developments in psychedelic research and therapy.

The conference will feature keynote speeches from industry leaders, panel discussions and workshops. Topics will range from the latest clinical trials to regulatory updates and investment opportunities in the psychedelics sector.

"The mental health crisis has quickly transitioned into a global pandemic and we need a solution fast," said William Potts, Co-Founder of Psych Capital Plc (AQSE: PSY). "We are thrilled to bring PSYCH Symposium back to London where we can host some of the leading minds in the industry who are focused on finding innovative solutions to healthcare that can tackle these issues in the very near future."

"The field of psychedelic healthcare is rapidly evolving, and we are excited to bring together leading experts to explore the latest developments and discuss how we can integrate psychedelics into mainstream medicine."

The PSYCH Symposium will take place on 6 July 2023, at The British Museum. Early bird registration is now open and is expected to sell out.

For more information and to register for the event, please visit: https://www.psychsymposium.com/

The Directors of the Company accept responsibility for the contents of this announcement.

Enquiries:

Company:

Joseph Colliver:

William Potts:

Peterhouse Capital Limited:

Corporate Adviser:

Guy Miller /Narisha Ragoonanthun: + 44 (0) 20 7469 0930

Corporate Broker

Lucy Williams: +44 (0) 20 7469 0930

Duncan Vasey: +44 (0) 20 7220 9797 (Direct)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXIIMTTMTBTBAJ

(END) Dow Jones Newswires

April 25, 2023 02:00 ET (06:00 GMT)

Shortwave Life Sciences (AQSE:PSY)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024

Shortwave Life Sciences (AQSE:PSY)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024